|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1995-1-27
|
|
pubmed:abstractText |
Penetration of cefprozil into the middle ear fluid was investigated in patients with chronic otitis media. A total of 89 patients ranging from 7 months to 11 years old participated in the study. The middle ear fluid was removed by ventilation tubes inserted through the tympanic membrane at times ranging from 0.38 to 5.97 h after oral administration of a single dose of 15 or 20 mg/kg of body weight. A blood sample was also collected as soon as the middle ear fluid was removed. Plasma samples were analyzed for the concentration of cefprozil by a high-performance liquid chromatographic assay. Middle ear fluid samples were analyzed for the concentration of cefprozil by a microbiological assay. The concentrations of cefprozil in plasma ranged from 0.38 to 15.97 micrograms/ml at the 15-mg/kg dose level and from 1.28 to 21.47 micrograms/ml at the 20-mg/kg dose level. The corresponding middle ear fluid concentrations of cefprozil ranged from 0.06 to 4.44 micrograms/ml and from 0.17 to 8.67 micrograms/ml, respectively. Cefprozil penetrates well into middle ear fluid in patients with chronic otitis media.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-1617039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2062625,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2126695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2154440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2684004,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2684005,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2952061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-2953304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3038010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3105449,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3495236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3496846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3560383,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-3606067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-6648747,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-6799415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-7142073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7811050-7200999
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2210-2
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7811050-Cephalosporins,
pubmed-meshheading:7811050-Child,
pubmed-meshheading:7811050-Child, Preschool,
pubmed-meshheading:7811050-Chronic Disease,
pubmed-meshheading:7811050-Dose-Response Relationship, Drug,
pubmed-meshheading:7811050-Exudates and Transudates,
pubmed-meshheading:7811050-Female,
pubmed-meshheading:7811050-Humans,
pubmed-meshheading:7811050-Infant,
pubmed-meshheading:7811050-Male,
pubmed-meshheading:7811050-Middle Ear Ventilation,
pubmed-meshheading:7811050-Otitis Media with Effusion
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Penetration of cefprozil into middle ear fluid of patients with otitis media.
|
|
pubmed:affiliation |
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Syracuse, New York 13221-4755.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
